F16 IL2 fusion protein (Philogen)

N/A

Report date: 2022/07/22 20:00:33

Base Information

Drug NameF16 IL2 fusion protein (Philogen)
Drug Alias NameTeleukinF-16-IL-2
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsSolid tumoursKidney NeoplasmsProstatic Neoplasms +[8
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyDenmark +[9
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPhilogen Spa
China Registration ClassN/A

Develop Information

Active CompaniesPhilogen Spa
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumoursKidney NeoplasmsProstatic Neoplasms +[7

Other Information

ATC CodeN/A
Related LinksN/A